Nycomed To Sell Norgine Moviprep In Russia

Nycomed, a privately owned global pharmaceutical company with a strong presence in Europe and Russia, has entered into a licencing agreement with Norgine, gaining exclusive rights to market Norgine’s bowel-cleansing laxative Moviprep, the world’s leading bowel cleansing brand. The deal covers Russia and the Commonwealth of Independent States (Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova,

Continue Reading

EMA Accepts Merck & Ariad’s Sarcoma Drug Filling

Merck & Co (also known as MSD) and partner Ariad Pharmaceuticals moved a step closer to EU approval for cancer treatment ridaforolimus yesterday when the European Medicines Agency agreed to start reviewing their marketing application for the drug. Ridaforolimus is an experimental oral mTOR inhibitor developed as a treatment for patients with metastatic soft-tissue or

Continue Reading

Melanoma Drug Zelboraf Approved by FDA

The US Food and Drug Administration approved Roche’s Zelboraf yesterday for the treatment of patients with advanced melanoma that is beyond the reach of surgery. Zelboraf (vemurafenib) was approved two months ahead of schedule by the FDA and is the second melanoma drug to be approved in 2011 after Bristol-Myers Squibb’s Yervoy (ipilimumab), which debuted

Continue Reading

GNS Announces Collaboration with BMS

GNS Healthcare have announced a collaboration with Bristol-Myers Squibb (BMS) to provide a computer model that can support virtual clinical trials in the field of immuno-inflammation. No financial terms were disclosed on the tie-up, under which GNS will take clinical and molecular information from a BMS clinical trial and will use its supercomputer-driven REFS (reverse-engineering

Continue Reading

Pharma Facebook Pages Open To Comments

From today (August 15th), most pharmaceutical company pages on Facebook are due to be open to comments for the first time, something which could strain the industry’s difficult relationship with social media. Many pharmaceutical companies only agreed to set up on Facebook in return for the ability to moderate and block comments on their pages,

Continue Reading

Drug Developers “Facing Complex Global Regulatory Requirements”

Experts have warned that as pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory complexity is forcing them to change the way they operate. “What a company does in one region can very likely affect how regulators treat it elsewhere,” according to Christopher-Paul Milne, associate director of

Continue Reading

Diabetes is pharma’s fastest-growing market

Diabetes is the pharmaceutical industry’s fastest-growing market, and the costs of preventing and treating the condition worldwide are forecast to rise from $376 billion in 2010 to $490 billion by 2030, according to new research.  285 million people, or 6.4% of the world’s adult population, are currently estimated to be living with diabetes, and this

Continue Reading

MS drug hits Phase II targets

Biogen Idec and Abbott Laboratories have reported promising results in a Phase IIb trial of daclizumab, their once-monthly injectable treatment for multiple sclerosis. Top-line results from the dose-ranging SELECT trial in patients with the relapsing-remitting form of MS indicate that treatment with daclizumab at a dose of 150mg given by subcutaneous injection once every four

Continue Reading

Allergan’s Botox gets EU approval for Incontinence

Allergan has been boosted by the news that Botox has received a positive agreement for approval in 14 European Union countries for treating certain patients with urinary incontinence. The recommendation from the Irish Medicines Board is for Botox (botulinum toxin type A) to be approved for the management of urinary incontinence in adults with neurogenic

Continue Reading